WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that it is set to join the Russell 3000® Index, according to a preliminary list of additions recently posted on www.russell.com. Targacept’s addition to the broad market Russell 3000 Index, which remains in place for one year, means automatic inclusion in the Russell 2000® Index. The 2008 reconstitution of the Russell indexes will take place after the market closes on June 27, 2008.